Management of Toxicities Associated With Immune Checkpoint Inhibitors

Abstract: Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune checkpoint inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs […]

The Effectiveness of Immune Checkpoint Inhibitors in the Neoadjuvant and Post-Neoadjuvant Breast Cancer Settings

H&O  Could you describe the design of the KEYNOTE-522 study?  LP  KEYNOTE-522 was a large, randomized, placebo-controlled phase 3 trial that tested pembrolizumab (Keytruda, Merck) as […]

Immunotherapy for Small Cell Lung Cancer: Established Applications and Novel Approaches

Abstract: Small cell lung cancer (SCLC) is a devastating disease that has a case fatality rate of more than 90% despite best available treatments. As a […]